3月16日 - ** 药物开发商科景生物COGT.O股价盘前上涨11.2%至37.8美元
** 该公司称 (link)，美国食品和药物管理局已接受对其实验性药物bezuclastinib的审查，该药物用于治疗一种被称为非晚期系统性肥大细胞增多症的疾病患者(NonAdvSM)
** 非晚期系统性肥大细胞增多症是一种罕见病，某些免疫细胞在体内堆积过多，导致皮肤潮红、胃部不适、疲倦和头痛等症状。
** COGT表示，已收到贝珠司替尼的目标行动日期为12月30日
** 如果涨势得以保持，该股有望打破六日连跌的局面
** 截至上次收盘，COGT今年累计下跌4.3%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.